Project: “Metabolic therapy of heart failure: which role for B vitamins”

Acronym HF-MetaB (Reference Number: JTC-2019_055)
Duration 01/05/2020 - 30/04/2023
Project Topic Heart failure (HF) is a major cause of death worldwide. Profound modulations of energy metabolism are involved in the development of HF, such as a drop in the cardiac levels of energy carrier compounds (ATP, Phosphocreatine (PCr)) and nicotinamide adenine dinucleotide (NAD+), a major coenzyme in energy generatione. In a previous mouse model of cardiac pressure overload, we were able to show the protective effect of diet supplementation of two vitamins, B12 and B9, stimulating the mitochondrial biogenesis pathways, or with nicotinamide riboside (NR), a recently characterized vitamin B3 which is a NAD+ precursor. Inasmuch as these treatments were given before the appearance of the first symptoms of HF in previous studies, we propose here to test the curative effect of a cocktail of these 3 B vitamins in symptomatic HF in mice. In a translational perspective toward clinics, we will also assess the impact of this vitamins cocktail in the context of standard medical HF care (β-blocker, ACE inhibitor). Finally, it is critically important to consider the sex differences in treatment of HF. Therefore our second aim is to compare the effect of the treatment between males and females that may differ according to the mitochondrial alterations in HF.
Network ERA-CVD
Call ERA-CVD Joint Transnational Call 2019

Project partner

Number Name Role Country
1 Paris Sud University Coordinator France
2 Université de Montréal Partner Canada
3 Slovak Academy of Sciences Partner Slovakia
4 Medical University of Vienna Partner Austria